Regenerex Pharma (RGPX) Depreciation & Amortization (CF) (2018 - 2025)

Regenerex Pharma (RGPX) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $1148.0 in Q3 2025.

• Depreciation & Amortization (CF) for Q3 2025 came in at $1148.0, up 166.98% year-over-year; the trailing twelve-month figure through Sep 2025 was $3268.0 (up 89.45% YoY), and the FY2025 annual result was $1726.0, up 23.02% from the prior year.
• Depreciation & Amortization (CF) retreated to $1148.0 in Q3 2025 per RGPX's latest filing, from $1259.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1259.0 in Q2 2025 and troughed at -$538.0 in Q3 2022.
• A 5-year average of $484.82 and a median of $430.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) sank 165.85% in 2022, then soared 430.49% in 2023.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $817.0 in 2021, then tumbled by 89.96% to $82.0 in 2022, then soared by 430.49% to $435.0 in 2023, then changed by 0.0% to $435.0 in 2024, then jumped by 163.91% to $1148.0 in 2025.
• Business Quant data shows RGPX's Depreciation & Amortization (CF) at $1148.0 in Q3 2025, $1259.0 in Q2 2025, and $426.0 in Q1 2025.